{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:49:43Z","timestamp":1785408583388,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"vor","delay-in-days":379,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.5604\/01.3001.0011.7398","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T06:25:00Z","timestamp":1525847100000},"page":"525-529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report"],"prefix":"10.1016","volume":"17","author":[{"given":"Elise J.","family":"Smolders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie B.","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"El-Sherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.5604\/01.3001.0011.7398_bib0005","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s11695-009-0014-5","article-title":"Metabolic\/bariatric surgery Worldwide 2008","volume":"19","author":"Buchwald","year":"2009","journal-title":"Obes Surg"},{"key":"10.5604\/01.3001.0011.7398_bib0010","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1007\/s11695-015-1657-z","article-title":"Bariatric Surgery Worldwide 2013","volume":"25","author":"Angrisani","year":"2015","journal-title":"Obes Surg"},{"key":"10.5604\/01.3001.0011.7398_bib0015","unstructured":"World Health Organization. Fact sheet #311: Obesity and overweight. Available at: http:\/\/www.who.int\/mediacentre\/ factsheets\/fs311\/en\/. Access: April 6 2017."},{"key":"10.5604\/01.3001.0011.7398_bib0020","doi-asserted-by":"crossref","unstructured":"Sinha A, Jayaraman L, Punhani D, Chowbey P. Enhanced Recovery after Bariatric Surgery in the Severely Obese, Morbidly Obese, Super-Morbidly Obese and Super-Super Morbidly Obese Using Evidence-Based Clinical Pathways: a Comparative Study. Obesity Surgery 2016; 1-9. Doi: 10.1007\/s11695-016-2366-y.","DOI":"10.1007\/s11695-016-2366-y"},{"key":"10.5604\/01.3001.0011.7398_bib0025","unstructured":"Pawlotsky JM, Aghemo A, Back D, Dusheiko G, Forns X, Negro F, Puoti M, et al. EASL Recommendations on Treatment of Hepatitis C 2016 [In press]. J Hepatol 2016. Doi: http:\/\/ dx.doi.org\/10.1016\/j.jhep.2016.09.001."},{"key":"10.5604\/01.3001.0011.7398_bib0030","unstructured":"EMA. Daklinza: Summary of Product Characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_ library\/EPAR_-_Product_Information\/human\/003768\/ WC500172848.pdf. Access: February 15 2015."},{"key":"10.5604\/01.3001.0011.7398_bib0035","unstructured":"EMA. Olysio: Summary of Product Characteristics. Available at: http:\/\/ec.europa.eu\/health\/documents\/community-register\/ 2014\/20140514128513\/anx_128513_en.pdf. Access: February 15 2015."},{"key":"10.5604\/01.3001.0011.7398_bib0040","unstructured":"EMA. Viekirax: Summary of Product Characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_ library\/EPAR_-_Product_Information\/human\/003839\/ WC500183997.pdf. Access: June 5 2015."},{"key":"10.5604\/01.3001.0011.7398_bib0045","unstructured":"EMA. Rebetol Product Information. Available at: http:\/\/ www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000246\/WC500048210.pdf. Access: March 02 2016."},{"key":"10.5604\/01.3001.0011.7398_bib0050","unstructured":"EMA. Harvoni: Summary of Product Characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/ document_library\/EPAR_-_Product_Information\/human\/ 003850\/WC500177995.pdf. Access: February 15 2015."},{"key":"10.5604\/01.3001.0011.7398_bib0055","unstructured":"EMA. Summary of Product characteristics Epclusa. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/ EPAR_-_Product_Information\/human\/00421 0\/ WC500211151.pdf. Access: 8 december 2016."},{"key":"10.5604\/01.3001.0011.7398_bib0060","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/hep.28467","article-title":"Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study","volume":"64","author":"Kwo","year":"2016","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7398_bib0065","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.28422","article-title":"Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)","volume":"64","author":"Lawitz","year":"2016","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7398_bib0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.20506","article-title":"Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C","volume":"41","author":"Ziol","year":"2005","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7398_bib0075","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: a new noninvasive method for assessment of hepatic fibrosis","volume":"29","author":"Sandrin","year":"2003","journal-title":"Ultrasound Med Biol"},{"key":"10.5604\/01.3001.0011.7398_bib0080","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/hep.1840190629","article-title":"Classification of chronic hepatitis: diagnosis, grading and staging","volume":"19","author":"Desmet","year":"1994","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7398_bib0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7398_bib0090","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.5604\/01.3001.0011.7398_bib0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL Recommendations on Treatment of Hepatitis C 2015","volume":"63","author":"Pawlotsky","year":"2015","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0011.7398_bib0100","unstructured":"Arends JE, Berden FA, Brouwer JT, Burger DM, Drenth JPH, Hoepelman AIM, Honkoop P, et al. Richtsnoer behandeling hepatitis C infectie. Available at: http:\/\/ www.hcvrichtsnoer.nl\/. Access: November 01 2016."},{"key":"10.5604\/01.3001.0011.7398_bib0105","unstructured":"AASLD\/IDSA\/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Available at: http:\/\/ www.hcvguidelines.org. Access: February 14 2015."},{"key":"10.5604\/01.3001.0011.7398_bib0110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/FTD.0b013e318205f892","article-title":"Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations","volume":"33","author":"Slavenburg","year":"2011","journal-title":"Ther Drug Monit"},{"key":"10.5604\/01.3001.0011.7398_bib0115","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchromb.2006.03.019","article-title":"Validation of liquid\/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients","volume":"835","author":"D\u2019Avolio","year":"2006","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci"},{"key":"10.5604\/01.3001.0011.7398_bib0120","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3851\/IMP1894","article-title":"Rapid viral response of once-daily TMC435 plus pegylated interferon\/ribavirin in hepatitis C genotype-1 patients: a randomized trial","volume":"16","author":"Manns","year":"2011","journal-title":"Antivir Ther"},{"key":"10.5604\/01.3001.0011.7398_bib0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3851\/IMP2994","article-title":"Ribavirin concentration determines treatment success of first-generation DAAbased chronic HCV therapy","volume":"21","author":"de Kanter","year":"2016","journal-title":"Antivir Ther"},{"key":"10.5604\/01.3001.0011.7398_bib0130","unstructured":"EMA. Sovaldi Product Information. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002798\/WC500160597.pdf. Access: February 29 2016."},{"key":"10.5604\/01.3001.0011.7398_bib0135","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin Pharmacokinet"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119302091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119302091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:38:37Z","timestamp":1761647917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268119302091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1665268119302091"],"URL":"https:\/\/doi.org\/10.5604\/01.3001.0011.7398","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.5604\/01.3001.0011.7398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}